Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

975 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oxaliplatin: results in colorectal carcinoma.
Carrato A, Gallego J, Díaz-Rubio E. Carrato A, et al. Among authors: gallego j. Crit Rev Oncol Hematol. 2002 Oct;44(1):29-44. doi: 10.1016/s1040-8428(01)00192-5. Crit Rev Oncol Hematol. 2002. PMID: 12398998 Review.
Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.
Rivera F, Galán M, Tabernero J, Cervantes A, Vega-Villegas ME, Gallego J, Laquente B, Rodríguez E, Carrato A, Escudero P, Massutí B, Alonso-Orduña V, Cardenal A, Sáenz A, Giralt J, Yuste AL, Antón A, Aranda E; Spanish Cooperative Group for Digestive Tumor Therapy. Rivera F, et al. Among authors: gallego j. Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1430-6. doi: 10.1016/j.ijrobp.2008.12.087. Epub 2009 Jun 18. Int J Radiat Oncol Biol Phys. 2009. PMID: 19540072 Clinical Trial.
Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma.
Rivera F, Galán M, Tabernero J, Cervantes A, Vega-Villegas ME, Gallego J, Laquente B, Rodríguez E, Carrato A, Escudero P, Massutí B, Alonso-Orduña V, Cardenal A, Sáenz A, Giralt J, Yuste AL, Antón A, Aranda E; Spanish Cooperative Group for Digestive Tumour Therapy (TTD). Rivera F, et al. Among authors: gallego j. Cancer Chemother Pharmacol. 2011 Jan;67(1):75-82. doi: 10.1007/s00280-010-1285-1. Epub 2010 Mar 3. Cancer Chemother Pharmacol. 2011. PMID: 20198372 Clinical Trial.
Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer.
Carrato A, Gómez A, Escudero P, Chaves M, Rivera F, Marcuello E, González E, Grávalos C, Constenla M, Manzano JL, Losa F, Maurel J, Dueñas R, Massuti B, Gallego J, Aparicio J, Antón A, Aranda E. Carrato A, et al. Among authors: gallego j. Clin Transl Oncol. 2013 Sep;15(9):705-11. doi: 10.1007/s12094-012-0993-x. Epub 2013 Jan 29. Clin Transl Oncol. 2013. PMID: 23359181 Clinical Trial.
TTD consensus document on the diagnosis and management of exocrine pancreatic cancer.
Benavides M, Abad A, Ales I, Carrato A, Díaz Rubio E, Gallego J, García-Foncillas J, Grávalos C, Laquente B, Pericay C, Rivera F, Tabernero J, Aranda E. Benavides M, et al. Among authors: gallego j. Clin Transl Oncol. 2014 Oct;16(10):865-78. doi: 10.1007/s12094-014-1177-7. Epub 2014 Apr 12. Clin Transl Oncol. 2014. PMID: 24728654 Review.
A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.
Salazar R, Capdevila J, Laquente B, Manzano JL, Pericay C, Villacampa MM, López C, Losa F, Safont MJ, Gómez A, Alonso V, Escudero P, Gallego J, Sastre J, Grávalos C, Biondo S, Palacios A, Aranda E. Salazar R, et al. Among authors: gallego j. BMC Cancer. 2015 Feb 26;15:60. doi: 10.1186/s12885-015-1053-z. BMC Cancer. 2015. PMID: 25886378 Free PMC article. Clinical Trial.
975 results